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Abstract
Background
The use of histamine-2 receptor antagonists (H2RA) in neonates is still debated because of
possible risk of infection, necrotizing enterocolitis (NEC) and increased mortality.
Aim
To review whether the use of H2RA in neonates admitted to neonatal intensive care units
(NICU) is associated with infection, NEC or mortality.
Materials and method
We performed a systematic search in PubMed, Web of Science and SCOPUS databases
using the terms “histamine-2 receptor antagonists”, “infection”, “necrotizing enterocolitis”,
“mortality”, “neonates” and related terms to identify studies published up to April 30, 2017.
We included studies conducted in hospitalized neonates and exposed to H2RA. The primary
outcomes were infection, NEC and mortality. We included reports of infections with clinical
signs and positive culture, and NEC according to Bell stages (stage�II) based on standard-
ised clinical and radiologic criteria. Among 1,144 studies identified, 10 fulfilled the selection
criteria. Information extracted included study design, sample size and number of partici-
pants, along with the outcomes of interest. We conducted a meta-analysis of adjusted data
and pooled estimates of infection, NEC and mortality are reported as odds ratios (OR) and
95% confidence intervals (95%CI).
Results
Ten studies were analysed. There were substantial associations between H2RA and infec-
tion (pooled OR: 2.09; 95%CI: 1.35–3.24; P = 0.001) and NEC (pooled OR: 2.81, 95%CI:
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1.19–6.64; P = 0.02) but not with the mortality risk (pooled OR: 1.76; 95%CI: 0.50–6.16; P:
0.38).
Conclusion
Current evidence suggests that H2RA is associated with an increased risk of infection and
NEC, but not with mortality in neonates admitted to NICU. The use of H2RA in neonates
must be stringently considered when necessary.
Introduction
Histamine-2 receptor antagonists (H2RA) are often prescribed off-label to neonates admitted
to neonatal intensive care units (NICU) [1] for prophylaxis or therapy of stress ulcers and gas-
troesophageal reflux disease (GERD). However, the safety and efficacy of H2RA in neonates is
still debated [2]. This is due to gastric acid secretions being one of the main non-immune
defenses against invading pathogens [3] and the sustained inhibition of gastric acid secretions
alters the bacterial ecology favoring the gastric colonization of enteric bacteria and may facili-
tate microbial translocation across the gut barrier because of decreased neutrophil activity
[4,5]. Studies have shown an increasing gastric pH within few minutes of H2RA administration
[6,7], with effects on the H2 receptors activation and modelling of the immune responses, espe-
cially in the production of inflammatory cytokines [8–10].
A 2014 systematic review of clinical trials conducted in 1 to 15 years old children reported
that H2RA were effective in reducing GERD signs and symptoms, but did not report adverse
effects in a measurable manner, precluding a quantitative analysis on drug safety [11]. Other
studies in neonates however have shown that H2RA may predispose to infections [3,12–14],
necrotising enterocolitis (NEC) [14,15] and death [14,16], but there are no systematic analyses
of this evidence.
We conducted a systematic review and meta-analysis to investigate whether the use of
H2RA in neonates admitted to NICU is associated with an increased risk of infection, NEC
and mortality.
Materials and methods
This study was conducted following the Meta-Analysis of Observational Studies in Epidemiol-
ogy (MOOSE) statement (S1 File) [17]. Institutional review board approval and informed con-
sent were not required for this systematic review and meta-analysis. A study protocol was
designed a priori and was registered in the PROSPERO database (registration number
CRD42017060887).
Search strategy and selection criteria
We performed a systematic review using PubMed, Web of Science and SCOPUS databases to
identify studies published up to April 30, 2017 without language restriction. Publications were
identified using the terms “histamine-2 receptor antagonists”, “infection”, “necrotizing entero-
colitis”, “mortality”, “neonates” and related terms. The full search strategy is described in the
S1 Table. Two independent reviewers (MSF and RNSS) screened titles and abstracts for rele-
vance and adequacy and disagreements were resolved by VSS and RQG. The manuscripts
selected were read in full to confirm their eligibility and their reference lists were scanned to
identify additional studies. We included studies conducted with neonates hospitalized in
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NICU and exposed to H2RA. We excluded studies in infants over 28 days old, those not con-
taining original material or reporting data from ambulatory patients and studies including
neonates with infections before initiating H2RA, congenital malformations or genetic syn-
dromes, mothers with HIV, rubella, toxoplasmosis, cytomegalovirus or hepatitis B and C.
Outcomes
The primary outcomes were infection, NEC and mortality. We included reports of nosocomial
infections with clinical signs and positive culture. NEC was classified according to Bell stages
and included children with Bell stage�II [18].
Secondary outcomes included pneumonia, sepsis and urinary tract infections (UTI). For
these outcomes, we consider studies that had defined a) pneumonia as the presence of clinical
signs associated with positive culture or radiological findings with suggestive signals of pulmo-
nary involvement by infectious agents (persistent infiltrate, consolidation and cavitation) and
abnormal laboratory tests; b) sepsis as the presence of signs suggestive of infection associated
with a positive blood culture, and c) UTI when there was a positive urine culture together with
clinical findings.
We analyzed the mortality at any time during the follow-up period, as reported in the study
included in the meta-analysis.
Data extraction and bias assessment
We used pre-formatted tables for data extraction, including author, publication year, country,
study design, sample size, number of participants with infections, NEC or death by H2RA
exposure. Not all studies reported the absolute numbers of the outcomes and frequencies were
calculated from percentages. For articles not available in electronic databases or data unavail-
able in the articles included, we attempted to contact the authors to obtain relevant informa-
tion. We had planned to extract data on the exposure time and dosage of H2RA to ascertain
duration of exposure and a dose safety gradient; however, it was not possible to obtain the data
for meta-analysis. The risk of bias for individual studies was assessed by two independent
reviewers using the Newcastle-Ottawa Scale (NOS) [19] and disagreements were resolved by
discussion.
Statistical analysis
We calculated the pooled odds ratio (OR) for the primary and secondary outcomes and used
forest plots to present effect sizes with 95% confidence intervals (95%CI). Pooled unadjusted
and adjusted estimates were calculated using Mantel-Haenszel and inverse variance methods,
respectively. The meta-analysis was performed using random-effects model. Two-tailed P-val-
ues<0.05 were used to determine statistical significance. Statistical heterogeneity was assessed
using the Cochran Q test [20] and quantified by the I2 index [21]. A subgroup analysis was per-
formed according to the study design (cohort or case-control).
Leave-one-out sensitivity analysis was conducted by omitting one study at a time and exam-
ining the influence of each study on the pooled effect size [22]. Analyses were performed using
Review Manager 5.3 (Cochrane IMS, Copenhagen, Denmark) and R-3.3.2 software (R Foun-
dation for Statistical Computing, Vienna, Austria).
Results
The literature search identified 1,144 records. After screening titles and abstracts, 35 full-text
articles were assessed for eligibility and 10 were included (Fig 1). Table 1 summarizes the main
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characteristics of the 10 studies. Five studies used a case-control design [13,23–26] and five
were cohorts [14,16,27–29]. No clinical trials were found. Nine studies focused on very-low
birth weight babies [13,14,16,23,25–29] and one considered the whole preterm population
(gestational age<37 weeks) [24]. Most studies reported only infection as an outcome
[13,14,25,27–29], two reported only NEC [23,24] and four included the three main outcomes
of infection, NEC and mortality [14,16,26,29].
Fig 1. Flowchart of studies for inclusion in the meta-analysis.
https://doi.org/10.1371/journal.pone.0214135.g001
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Table 1. Main characteristics of the studies analysed.
Study Country Study design Population Subject characteristics Risk factors used Statistics strategy Outcome
Rojas et al.
(2005) [27]
Colombia Cohort
prospective
Very Low
Birth Weight
Birth weight: <2000g.
Gestational age: <35
weeks
Maternal factors: age, fever (>38˚C),
prenatal antibiotics, prenatal steroids,
premature ruptured membranes, type of
delivery (vaginal, elective caesarean
section, emergency). Infant factors: birth
weight, gestational age, gender,
mechanical ventilation, oxygen, postnatal
antibiotics, catheters (central and non-
central), parenteral nutrition and gastric
tube for enteral nutrition.
Univariate and
Multivariate
logistic regression
Infection
Guillet et al.
(2006) [23]
USA Case-control Very Low
Birth Weight
Birth weight: 401g-
1500g. Gestational age:
not available
Maternal factors: not available. Infant
factors: birth weight, gender, race, site of
birth and Apgar score.
Univariate and
Multivariate
logistic regression
Necrotizing
enterocolitis
Bianconi
et al. (2007)
[13]
USA Case-control Very Low
Birth Weight
Birth weight: not
available. Gestational
age: not available
Maternal factors: not available. Infant
factors: birth weight, gestational age,
gender, length of stay in NICU, duration
of total parenteral nutrition,
pharmaceutical substances used and
duration for central vascular catheters.
Univariate
analysis
Infection
Afjeh et al.
(2012) [28]
Iran Cohort
retrospective
Very Low
Birth Weight
Birth weight: <1500g.
Gestational age: <37
weeks
Maternal factors: age, fever (>38˚C),
prenatal antibiotics, prenatal steroids,
premature ruptured membranes, type of
delivery (vaginal, elective caesarean
section, emergency). Infant factors: birth
weight, gestational age, gender, Apgar
score, intubation at delivery room,
duration of mechanical ventilation,
duration of oxygen therapy, postnatal
antibiotics, chest tube, catheters (central
and non-central), parenteral nutrition and
gastric tube for enteral nutrition.
Univariate and
Multivariate
logistic regression
Infection
Terrin et al.
(2012) [14]
Italian Cohort
prospective
Very Low
Birth Weight
Birth weight: 401-
1500g. Gestational age:
24–32 weeks
Maternal factors: age, fever (>38˚C),
prenatal antibiotics, prenatal steroids,
premature ruptured membranes, type of
delivery (vaginal, elective or emergency
caesarean section).
Infant factors: birth weight, gestational
age, gender, Apgar, duration of
mechanical ventilation, oxygen therapy,
postnatal antibiotics, catheters (central
and non-central), parenteral nutrition and
gastric tube for enteral nutrition.
Univariate and
Multivariate
logistic regression
Infection,
necrotizing
enterocolitis and
mortality
Bilali et al
(2013) [24]
Greece Case-control Pre-term Birth weight: not
available. Gestational
age: <37 weeks
Not available. Univariate and
Multivariate
logistic regression
Necrotizing
enterocolitis
Gupta et al.
(2013) [25]
USA Case-control Very Low
Birth Weight
Birth weight: <1500g
Gestational age: <34
weeks
Maternal factors: age, fever (oral
temperature >38˚C), antibiotics, steroids,
caffeine use, premature ruptured
membranes, chorioamnionitis, type of
delivery.
Infant factors: birth weight, gestational
age, gender and formula feeding.
Univariate
analysis
Infection
Singh et al.
(2016) [26]
Australia Case-control Very Low
Birth Weight
Birth weight: < 1500g
Gestational age: not
available
Maternal factors: not available.
Infant factors: birth weight, gestational
age, gender, Apgar, patent ductus
arteriosus, mechanical ventilation, oxygen
therapy, continuous positive airway
pressure, postnatal antibiotics, catheters
(central and non-central), parenteral
nutrition, type of feeding, gastric tube for
enteral nutrition and length of hospital
stay.
Univariate
analysis
Infection,
necrotizing
enterocolitis and
mortality
(Continued)
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The risk of bias assessments are summarized in Tables 2 and 3, respectively. Overall, cohort
studies had a lower risk of bias than case-control studies. The use of different criteria across
studies for the selection of comparison groups (not exposed to H2RA) may have introduced a
high risk of bias, especially among case-control studies.
Seven studies involving 129,850 subjects were included in the pooled OR estimation for
infection. Of these, 3,543 (17.0%) of 20,803 neonates receiving H2RA had infections compared
to 7,801 (7.2%) of 109,047 not exposed to H2RA, resulting in a pooled OR of 3.38 (95%CI:
1.92–5.94; P <0.001) (Fig 2A). There was substantial between-study heterogeneity (I2: 92%;
95%CI: 86.2% - 95.4%) and the sub-group meta-analysis demonstrated cohort studies influ-
enced substantially the pooled OR. Based on studies [27,28] that had adjusted values, the
pooled OR for infection was 2.09 (95%CI: 1.35–3.24; P<0.001) and the between-study hetero-
geneity was 0% (Fig 2B).
Some studies presented data for infection categories (Fig 3A–3C). Five studies had data for
sepsis [13,14,16,26,29] and the pooled unadjusted OR was 2.75 (95%CI: 1.51–5.02; P: 0.001)
Table 1. (Continued)
Study Country Study design Population Subject characteristics Risk factors used Statistics strategy Outcome
Romaine
et al. (2016)
[16]
USA Cohort
prospective
Very Low
Birth Weight
Birth weight: <1500g.
Gestational age
(median): <32 weeks
Maternal factors: type of delivery (vaginal
or caesarean section).
Infant factors: birth weight, gestational
age, gender, Apgar, mechanical
ventilation, oxygen therapy, inotropic
support and neutropenia.
Univariate
analysis
Infection,
necrotizing
enterocolitis and
mortality
Santana
et al. (2017)
[29]
Brazil Cohort
retrospective
Very Low
Birth Weight
Birth weight (median):
<1500g;.Gestational
age (median): <34
weeks
Maternal factors: age, fever (oral
temperature >38˚C), prenatal care,
premature rupture of membranes, type of
delivery (vaginal or caesarean section),
hypertension, Diabetes mellitus,
gestational diabetes.
Infant factors: birth weight, gestational
age, gender, Apgar, duration of
mechanical ventilation, oxygen therapy,
duration of catheters (central and non-
central), duration of parenteral nutrition
and duration of gastric tube for enteral
nutrition.
Univariate
analysis
Infection,
necrotizing
enterocolitis and
mortality
https://doi.org/10.1371/journal.pone.0214135.t001
Table 2. Assessment of study quality and risk of bias from case-control studies.
Study Selection Comparability Exposure
Adequate
case
definition
Representativeness of
cases
Selection of
controls
Definition of
controls
Case and control
are comparable
Ascertainment of
exposure
Same method of
ascertainment for cases
and controls
Non-
response
rate
Guillet et al.,
2006 [23]
Yes Yes No No Yes Yes Yes No
Bianconi
et al., 2007
[13]
Yes No No No Yes Yes Yes No
Bilali et al.,
2013 [24]
Yes Yes No Yes Yes Yes Yes No
Gupta et al.,
2013 [25]
Yes Yes No No Yes No Yes No
Singh et al.,
2016 [26]
Yes Yes No Yes Yes Yes Yes No
https://doi.org/10.1371/journal.pone.0214135.t002
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(I2: 86%; 95%CI: 68.9%-93.6%). Subgroup analysis showed an association between sepsis and
H2RA in cohort studies (OR: 2.57; 95%CI: 2.46–2.69; P <0.001) (I2: 0%; 95%CI: 0%-86.0%).
Three studies reported pneumonia and urinary tract infections [14,26,29] with pooled ORs of
2.93 (95%CI: 1.45–5.92; P: 0.003) (I2: 0%; 95%CI: 0%-82.1%) and 8.73 (95%CI: 2.38–31.98; P:
0.001) (I2: 0%; 95%CI 0%-70.7%), respectively.
Unadjusted analyses from the three cohort studies evaluating NEC [14,16,29] indicated an
association with H2RA (Fig 4A). Likewise, the meta-analysis of adjusted data [14,23,24]
reported substantial association between NEC and H2RA (pooled OR: 2.81; 95%CI: 1.19–6.64;
P: 0.02) (I2: 58%; 95% CI 0%-88.2%) (Fig 4B).
Fig 5 shows that the use of H2RA was not associated with mortality (pooled OR: 1.76; 95%
CI: 0.50–6.16; P: 0.38) (I2: 83%; 95% CI: 80.6%-96.0%).
Table 3. Assessment of study quality and risk of bias from cohort studies.
Study Selection Comparability Outcome
Representativeness of the
exposure cohort
Selection of the
non-exposed
cohort
Ascertainment of
exposure
Without
outcome in the
start
Cohorts are
comparable
Assessment of
outcome
Length of
follow-up
Adequacy of
follow-up
Rojas et al.,
2005 [27]
No No Yes No Yes Yes No Yes
Afjeh et al.,
2012 [28]
No No Yes No Yes Yes Yes Yes
Terrin et al.,
2012 [14]
Yes Yes Yes Yes Yes Yes Yes Yes
Romaine
et al., 2016
[16]
Yes Yes Yes Yes Yes Yes Yes Yes
Santana
et al., 2017
[29]
Yes Yes Yes Yes Yes Yes Yes Yes
https://doi.org/10.1371/journal.pone.0214135.t003
Fig 2. Forest Plot for infection outcome. A) unadjusted and B) adjusted pooled OR for infection.
https://doi.org/10.1371/journal.pone.0214135.g002
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Discussion
The frequent off-label use of H2RA in neonates steered the European Medicines Agency and
the US Food and Drug Administration to encourage studies on their safety and agencies
responsible for drug regulations increased their search for information on their adverse effects
in paediatric populations [2,14]. These initiatives has resulted in an increased number of stud-
ies, providing an opportunity to further ascertain adverse effects. In this systematic review and
meta-analysis, we found that the use of H2RA in neonates is associated with increased risk of
infections and NEC, but not with mortality.
Gastric fluid is an important non-immune barrier against pathogens [3] and the sustained
inhibition of gastric acid secretion increases the pH and modifies the gastric microbiota [4,5].
Fig 3. Forest Plot for sepsis, pneumonia and urinary tract infection. A) Unadjusted pooled OR for sepsis, B)
Unadjusted pooled OR for pneumonia and C) Unadjusted pooled OR for urinary tract infection.
https://doi.org/10.1371/journal.pone.0214135.g003
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The effects of H2RA administration are not restricted to the gastric pH, since they also increase
the production of pro-inflammatory cytokines and reduce immunological responses to infec-
tion [8–10].
The main reasons for the prescription of H2RA in NICUs are the management of GERD
and the prophylaxis and treatment of stress ulcers, usually caused by other drugs [11]. How-
ever, neonates receiving H2RA are more likely to exhibit GERD-like symptoms, resulting in a
false perception that GERD is persisting, leading in turn to an increase of drug dosage and
treatment duration [7]. Several studies have reported an average of 18 days between H2RA
administration and the occurrence of infection [14,30] and 19 days for the occurrence of NEC
[23], although one study from Brazil reported that infections started 6 days after H2RA use
[29].
Only two studies evaluated whether the H2RA dosage was associated with unfavourable
outcomes, as neonates who developed infection or NEC had received higher doses than chil-
dren without these outcomes, but these differences were not statistically significant [14,29]. It
Fig 4. Forest Plot for necrotizing enterocolitis (NEC). A) Unadjusted and B) Adjusted pooled OR for NEC.
https://doi.org/10.1371/journal.pone.0214135.g004
Fig 5. Forest Plot for mortality outcome.
https://doi.org/10.1371/journal.pone.0214135.g005
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is also noteworthy that the studies had used a wide H2RA dose ranges, making it difficult to
identify a safe and effective dose.
This meta-analysis also found an association between H2RA use and pneumonia, sepsis,
and UTI. It is well established that the inhibition of gastric acid secretion alters the bacterial
ecology favoring gastric colonization by enteric bacteria and may facilitate microbial transloca-
tion across the stomach barrier [4,5], which may contribute to the development of pneumonia
and sepsis [31]. Although the increased risk of pneumonia and sepsis involves gastric coloniza-
tion with gram-negative bacteria [31], the results of the studies included in this review do not
support this assertion. Although Rojas et al. (2005) [27] and Terrin et al. (2012) [14] studies
reported a higher prevalence of gram-negative microorganisms, et al. (2007) [13] reported the
same proportion of gram-negative and positive microorganisms among neonates receiving
and not receiving H2RA.
The prolonged use of mechanical ventilation, central and peripheral catheters, parenteral
nutrition and other devices in NICU is also associated with an increased risk of infection [32–
37]. Although some studies in this meta-analysis controlled for these factors [14,23,24,27–29],
= , the regression model still identified an association with H2RA.
Gestational age and low birth weight also increase the risk of nosocomial infections and
NEC[38]. However, after controlling for these factors, the use of H2RA was independently
associated with infection and NEC.
Although there is not enough information to assess whether H2RA increase the length of
hospitalization, two studies reported a potential increase in hospitalization time [14,29], and
further studies should be encouraged to generate this information in neonates.
The combined analysis of case-control and cohort studies did not show an association
between H2RA use and mortality. However, there was large heterogeneity between studies and
a paucity of quality data to examine the effect of H2RA and mortality, which may have resulted
in a type II error. Further studies are needed to generate sufficient data to examine this
association.
Our findings should be interpreted with caution as the number of studies showing the
adverse effects for H2RA use in neonates admitted to NICU is small. All studies included were
observational and treatments were not randomised. While the meta-analysis of cohort studies
showed an association between H2RA and increased risk of infection, NEC and death, these
associations were not fully evident in the case-control studies. Some studies had poor quality
which may increase the risk of bias. Moreover, it was not possible to perform a funnel plot
analysis due to the small number of studies. Finally, it was not possible to identify safe dosage
thresholds or usage time for H2RA in neonates due to the scarcity of data and the wide varia-
tion reported between and within the studies.
Despite these limitations, current available evidence shows an association between the use
of H2RA, the risk of infections and NEC in neonates. Further safety studies including well
defined patient groups are needed to increase the evidence for their safe use in neonates and to
support the development of guidelines by regulatory agencies. In the meantime, the use of
H2RAin neonates must be stringently considered, when necessary.
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